These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8917062)

  • 1. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy.
    Michelucci R; Cipolla G; Passarelli D; Gatti G; Ochan M; Heinig R; Tassinari CA; Perucca E
    Epilepsia; 1996 Nov; 37(11):1107-10. PubMed ID: 8917062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of nisoldipine coat-core.
    Heinig R
    Clin Pharmacokinet; 1998 Sep; 35(3):191-208. PubMed ID: 9784933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients.
    Chandler MH; Clifton GD; Lettieri JT; Mazzu AL; Allington DR; Thieneman AC; Foster TS; Harrison MR
    J Clin Pharmacol; 1992 Jun; 32(6):571-5. PubMed ID: 1634646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form.
    Schaefer HG; Heinig R; Ahr G; Adelmann H; Tetzloff W; Kuhlmann J
    Eur J Clin Pharmacol; 1997; 51(6):473-80. PubMed ID: 9112062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.
    Bailey DG; Arnold JM; Strong HA; Munoz C; Spence JD
    Clin Pharmacol Ther; 1993 Dec; 54(6):589-94. PubMed ID: 8275614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.
    Marques MP; Coelho EB; Dos Santos NA; Geleilete TJ; Lanchote VL
    Eur J Clin Pharmacol; 2002 Dec; 58(9):607-14. PubMed ID: 12483453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.
    Langtry HD; Spencer CM
    Drugs; 1997 May; 53(5):867-84. PubMed ID: 9129871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
    Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
    Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of age and liver disease on the pharmacokinetics of the calcium antagonist, nisoldipine.
    Davidsson GK; Edwards JS; Davidson C
    Curr Med Res Opin; 1995; 13(5):285-97. PubMed ID: 7555038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy.
    Pattanaik S; Hota D; Prabhakar S; Kharbanda P; Pandhi P
    Phytother Res; 2006 Aug; 20(8):683-6. PubMed ID: 16767797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
    Sachdeo R; Wagner ML; Sachdeo S; Shumaker RC; Lyness WH; Rosenberg A; Ward D; Perhach JL
    Epilepsia; 1999 Aug; 40(8):1122-8. PubMed ID: 10448826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.
    Levy RH; Ragueneau-Majlessi I; Garnett WR; Schmerler M; Rosenfeld W; Shah J; Pan WJ
    J Clin Pharmacol; 2004 Nov; 44(11):1230-4. PubMed ID: 15496640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction.
    Pisani F; Fazio A; Artesi C; Russo M; Trio R; Oteri G; Perucca E; Di Perri R
    J Neurol Neurosurg Psychiatry; 1992 Feb; 55(2):126-7. PubMed ID: 1538217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type.
    Schmidt D; Haenel F
    Neurology; 1984 Sep; 34(9):1252-5. PubMed ID: 6540414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine.
    Heinig R; Adelmann HG; Ahr G
    Eur J Clin Pharmacol; 1999 Mar; 55(1):57-60. PubMed ID: 10206086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine.
    Schmidt D; Einicke I; Haenel F
    Arch Neurol; 1986 Mar; 43(3):263-5. PubMed ID: 3947275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a delayed-action phenytoin preparation on blood phenytoin concentration.
    Bochner F; Hooper WD; Tyrer JH; Eadie MJ
    J Neurol Neurosurg Psychiatry; 1972 Oct; 35(5):682-4. PubMed ID: 5084136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparison of two prediction methods.
    Kerrick JM; Wolff DL; Graves NM
    Ann Pharmacother; 1995 May; 29(5):470-4. PubMed ID: 7655129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenytoin levels in catamenial epilepsy.
    Kumar N; Behari M; Ahuja GK; Jailkhani BL
    Epilepsia; 1988; 29(2):155-8. PubMed ID: 3349966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.